This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siminoff, L. A. Articles by Shen, Q. Search for Related Content PubMed PubMed Citation Articles by Siminoff, L. A. Articles by Shen, Q. Social Bookmarking                            What's this?

Factors That Predict the Referral of Breast Cancer Patients Onto Clinical Trials by Their Surgeons and Medical Oncologists

From the Case Western Reserve University, Cleveland, OH.

Address reprint requests to Laura Siminoff, PhD, School of Medicine WG-37, Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106-4961; email LAS5{at}po.cwru.edu

PURPOSE: To improve understanding of physicians’ reluctance to refer patients to clinical trials.

METHODS: This study was conducted in a large metropolitan region from 1993 to 1995 using a two-staged population-based sampling strategy. A total of 147 physicians discussed 245 patient cases and their own knowledge, attitudes, and practices toward clinical trials.

RESULTS: Ninety-three patients (38.0%) were offered a trial, and 49 (52.7%) of them agreed to participate. Forty-five patients (18.4%) actually received their adjuvant therapy on trial. Older patients and those with a poorer prognosis were less likely to be referred. Patients who delayed their decision were more than three times as likely to participate in a trial and more than eight times as likely to participate when they were reported to be actively involved in making the decision. Generally, physicians in university settings and who had formal support from a cooperative group were more likely to refer patients to trials. More specifically, surgeons referred more patients to trials when they felt comfortable explaining trials or believed that treatment should not stray from protocol. Oncologists were less likely to make referrals if they perceived the paperwork to be onerous or entry requirements to be too stringent. Surgeons’ participation in recommending adjuvant therapy to patients resulted in more trial referrals unless they treated their patients with tamoxifen.

CONCLUSION: (1) Physicians still need to overcome attitudinal and practical barriers to trial participation, (2) more support for physicians is needed, (3) surgeons may play a pivotal role in the recruitment of patients to adjuvant therapy trials, and (4) garnering patient enthusiasm for trial participation and involving them in the choice of adjuvant therapy may be key components to increasing trial enrollment.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. P. Williams, P. B. Mullan, and D. Todem Moving from theory to practice: implementing the Kin KeeperSM Cancer Prevention Model Health Educ. Res., April 1, 2009; 24(2): 343 - 356. [Abstract] [Full Text] [PDF]

				R. L. Comis, J. D. Miller, D. D. Colaizzi, and L. G. Kimmel Physician-Related Factors Involved in Patient Decisions to Enroll Onto Cancer Clinical Trials J. Oncol. Pract, March 1, 2009; 5(2): 50 - 56. [Abstract] [Full Text] [PDF]

				L. A. Siminoff Why Learning to Communicate With Our Patients Is So Important: Using Communication to Enhance Accrual to Cancer Clinical Trials J. Clin. Oncol., June 1, 2008; 26(16): 2614 - 2615. [Full Text] [PDF]

				N. E. Avis, K. W. Smith, C. L. Link, G. N. Hortobagyi, and E. Rivera Factors Associated With Participation in Breast Cancer Treatment Clinical Trials J. Clin. Oncol., April 20, 2006; 24(12): 1860 - 1867. [Abstract] [Full Text] [PDF]

				P. J. Embi, A. Jain, J. Clark, S. Bizjack, R. Hornung, and C. M. Harris Effect of a Clinical Trial Alert System on Physician Participation in Trial Recruitment Arch Intern Med, October 24, 2005; 165(19): 2272 - 2277. [Abstract] [Full Text] [PDF]

				C. A. Townsley, R. Selby, and L. L. Siu Systematic Review of Barriers to the Recruitment of Older Patients With Cancer Onto Clinical Trials J. Clin. Oncol., May 1, 2005; 23(13): 3112 - 3124. [Abstract] [Full Text] [PDF]

				G. G. Kimmick, B. L. Peterson, A. B. Kornblith, J. Mandelblatt, J. L. Johnson, J. Wheeler, R. Heinze, H. J. Cohen, and H. B. Muss Improving Accrual of Older Persons to Cancer Treatment Trials: A Randomized Trial Comparing an Educational Intervention With Standard Information: CALGB 360001 J. Clin. Oncol., April 1, 2005; 23(10): 2201 - 2207. [Abstract] [Full Text] [PDF]

				S.J. Wei, J.M. Metz, C. Coyle, M. Hampshire, H.A. Jones, S. Markowitz, and A.K. Rustgi Recruitment of Patients Into an Internet-Based Clinical Trials Database: The Experience of OncoLink and the National Colorectal Cancer Research Alliance J. Clin. Oncol., December 1, 2004; 22(23): 4730 - 4736. [Abstract] [Full Text] [PDF]

				L. Talarico, G. Chen, and R. Pazdur Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration J. Clin. Oncol., November 15, 2004; 22(22): 4626 - 4631. [Abstract] [Full Text] [PDF]

				J. M. Watters, J. C. Yau, K. O'Rourke, E. Tomiak, and S. Z. Gertler Functional status is well maintained in older women during adjuvant chemotherapy for breast cancer Ann. Onc., December 1, 2003; 14(12): 1744 - 1750. [Abstract] [Full Text] [PDF]

				M. M. Kemeny, B. L. Peterson, A. B. Kornblith, H. B. Muss, J. Wheeler, E. Levine, N. Bartlett, G. Fleming, and H. J. Cohen Barriers to Clinical Trial Participation by Older Women With Breast Cancer J. Clin. Oncol., June 15, 2003; 21(12): 2268 - 2275. [Abstract] [Full Text] [PDF]

				D. P. Goldman, S. H. Berry, M. S. McCabe, M. L. Kilgore, A. L. Potosky, M. L. Schoenbaum, M. Schonlau, J. C. Weeks, R. Kaplan, and J. J. Escarce Incremental Treatment Costs in National Cancer Institute-Sponsored Clinical Trials JAMA, June 11, 2003; 289(22): 2970 - 2977. [Abstract] [Full Text] [PDF]

				B. R. Cassileth Clinical Trials: Time for Action J. Clin. Oncol., March 1, 2003; 21(5): 765 - 766. [Full Text] [PDF]

				R. L. Comis, J. D. Miller, C. R. Aldige, L. Krebs, and E. Stoval Public Attitudes Toward Participation in Cancer Clinical Trials J. Clin. Oncol., March 1, 2003; 21(5): 830 - 835. [Abstract] [Full Text] [PDF]

				G. I. Cohen Clinical Research by Community Oncologists CA Cancer J Clin, March 1, 2003; 53(2): 73 - 81. [Abstract] [Full Text]

				A. I. Neugut and V. R. Grann Referral to Medical Oncologists: Are There Barriers at the Gate? J. Clin. Oncol., April 1, 2002; 20(7): 1716 - 1718. [Full Text] [PDF]